Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 161 | 46% |
| 2020 | 2 | 120 | 50% |
| 2021 | 2 | 138 | 53% |
| 2022 | 3 | 140 | 54% |
| 2023 | 2 | 108 | 57% |
| 2024 | 3 | 119 | 59% |
| 2025 from claims | – | 149 121–175 | 63% |
| 2026 forecast | – | 159 124–199 | 62% |
| 2027 forecast | – | 162 120–214 | 63% |
| 2028 forecast | – | 164 116–227 | 64% |
| 2029 forecast | – | 167 114–240 | 65% |
| 2030 forecast | – | 170 111–252 | 65% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Connecticut; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 22 | 1,661+10%/yr | +10%/yr | 0.9 | 48% | 3,360 in 2030+12%/yr |
| Pennsylvania | 19 | 908−0.7%/yr | −0.7%/yr | 0.7 | 27% | 1,830 in 2030+12%/yr |
| Massachusetts | 12 | 677+16%/yr | +16%/yr | 0.7 | 46% | 1,170 in 2030+9.5%/yr |
| New Jersey | 4 | 287+0.9%/yr | +0.9%/yr | 0.3 | 22% | 820 in 2030+19%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 40 | 2,686−4.5%/yr | −4.5%/yr | 8.71.0× | 23% | 2,760 in 2030+0.5%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with New York
Exact Sciences leads with 71% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 13 companies reported engagement with Connecticut’s surgeons worth $75K in consulting, speaking, meals and travel tied to these products, about $25K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.